Quick Takeaways: Why It Matters? AKS-699 is being positioned as a long-interval, owner-friendly alternative to monthly IL‑31 biologics like Cytopoint in canine atopic dermatitis. The favorable efficacy and tolerability profile in preclinical work (only mild, transient injection-site r...
Quick Takeaways Why It Matters? Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits...
